Drugs giant seeks global agency

Killgren, Lucy
February 1999
Marketing Week;2/25/1999, Vol. 22 Issue 4, p12
Trade Publication
Reports that pharmaceutical giant Aventis, formed by the merger of Rhone-Poulenc and Hoechst, is seeking a global advertising agency to create a worldwide campaign to launch its new name. Five agencies Aventis has talked to; Background information on products.


Related Articles

  • Aventis draws praise from analysts. Mirasol, Feliza // Chemical Market Reporter;12/14/98, Vol. 254 Issue 24, p10 

    Highlights analysts' views on Aventis, the life sciences company created by Hoechst AG and Rhone-Poulenc SA. Research and development budget for Aventis; Aventis' need to strengthen its operations to post the high profits of other giant pharmaceutical manufacturers.

  • R&D Times Two. Stevens, Tim // Industry Week/IW;05/07/2001, Vol. 250 Issue 7, p49 

    Deals with the integration of research and development (R&D) departments of merging companies. Ways by which merging companies can help their R&D staff through the integration; Benefits of the R&D integration to Aventis, the company formed by the merger between Hoechst AG and Rhone-Poulenc SA;...

  • Aventis SA. Gee, Jack // Industry Week/IW;06/07/99, Vol. 248 Issue 11, p30 

    Presents information on the merger of Hoechst AG and Rhone-Poulenc SA. Details on Aventis SA, the life-sciences company which came out of the merger; Discussion on the plans for Aventis.

  • Carat poised for ...20m Aventis win.  // Marketing Week;7/29/1999, Vol. 22 Issue 26, p12 

    Reveals that Carat is the favorite to win a pitch for the global media account for Aventis, the pharmaceutical company to be formed from the merger of Rhone-Poulenc and Hoechst. Total value of the media account.

  • New Life-Science Giant Aventis To Overhaul R&D. Blau, John // Research Technology Management;Jan/Feb2000, Vol. 43 Issue 1, p4 

    Reports on the creation of Aventis SA, a company created from the merger of Hoechst AG and Rhone-Poulenc SA. Number of employees of the company; Total volume of sales of the company; Projected savings the companies will get from their merger; Goal of the merger.

  • EC Forces Aventis To Divest Business.  // Chemical Market Reporter;08/16/99, Vol. 256 Issue 7, p8 

    Reports that Hoechst and Rhone-Poulenc have to license or sell some of their businesses in pharmaceuticals and agrochemicals to gain the European Commission's approval for their merger into Aventis. Plan of the companies for their cobalamines sector; Other plans of the companies.

  • Hoechst Shareholders Obtain Aventis Stock.  // Chemical Market Reporter;12/06/99, Vol. 256 Issue 23, p6 

    Deals with the negotiations made on the merger between Hoechst and Rhone-Poulenc. Plan of the companies to create the life sciences company Aventis; Trading of Aventis shares in the stock exchanges.

  • Aventis: New Giant on the Block. Alperowicz, Natasha // Chemical Week;2/17/1999, Vol. 161 Issue 6, p55 

    Provides information on Aventis, a combination of Hoechst's and Rhone-Poulenc's (RP) pharmaceutical, agricultural and veterinary businesses. Views of Igor Landau, president of RP and chairman designate of Aventis Pharma; Idea behind the merger; Total savings from the merger.

  • Hoechst, RP detail plans for a two-step merger. SCOTT, ALEX // Chemical Week;12/9/1998, Vol. 160 Issue 47, p18 

    Details the plans of Hoechst and Rhone-Poulenc to merge and form a life sciences company. Base of the life sciences business; Process of the merger; Negotiation between Hoechst and AgrEvo.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics